Cargando…

Deciding when to stop: efficient experimentation to learn to predict drug-target interactions

BACKGROUND: Active learning is a powerful tool for guiding an experimentation process. Instead of doing all possible experiments in a given domain, active learning can be used to pick the experiments that will add the most knowledge to the current model. Especially, for drug discovery and developmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Temerinac-Ott, Maja, Naik, Armaghan W, Murphy, Robert F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495685/
https://www.ncbi.nlm.nih.gov/pubmed/26153434
http://dx.doi.org/10.1186/s12859-015-0650-9
_version_ 1782380290349465600
author Temerinac-Ott, Maja
Naik, Armaghan W
Murphy, Robert F
author_facet Temerinac-Ott, Maja
Naik, Armaghan W
Murphy, Robert F
author_sort Temerinac-Ott, Maja
collection PubMed
description BACKGROUND: Active learning is a powerful tool for guiding an experimentation process. Instead of doing all possible experiments in a given domain, active learning can be used to pick the experiments that will add the most knowledge to the current model. Especially, for drug discovery and development, active learning has been shown to reduce the number of experiments needed to obtain high-confidence predictions. However, in practice, it is crucial to have a method to evaluate the quality of the current predictions and decide when to stop the experimentation process. Only by applying reliable stopping criteria to active learning can time and costs in the experimental process actually be saved. RESULTS: We compute active learning traces on simulated drug-target matrices in order to determine a regression model for the accuracy of the active learner. By analyzing the performance of the regression model on simulated data, we design stopping criteria for previously unseen experimental matrices. We demonstrate on four previously characterized drug effect data sets that applying the stopping criteria can result in upto 40 % savings of the total experiments for highly accurate predictions. CONCLUSIONS: We show that active learning accuracy can be predicted using simulated data and results in substantial savings in the number of experiments required to make accurate drug-target predictions.
format Online
Article
Text
id pubmed-4495685
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44956852015-07-09 Deciding when to stop: efficient experimentation to learn to predict drug-target interactions Temerinac-Ott, Maja Naik, Armaghan W Murphy, Robert F BMC Bioinformatics Research Article BACKGROUND: Active learning is a powerful tool for guiding an experimentation process. Instead of doing all possible experiments in a given domain, active learning can be used to pick the experiments that will add the most knowledge to the current model. Especially, for drug discovery and development, active learning has been shown to reduce the number of experiments needed to obtain high-confidence predictions. However, in practice, it is crucial to have a method to evaluate the quality of the current predictions and decide when to stop the experimentation process. Only by applying reliable stopping criteria to active learning can time and costs in the experimental process actually be saved. RESULTS: We compute active learning traces on simulated drug-target matrices in order to determine a regression model for the accuracy of the active learner. By analyzing the performance of the regression model on simulated data, we design stopping criteria for previously unseen experimental matrices. We demonstrate on four previously characterized drug effect data sets that applying the stopping criteria can result in upto 40 % savings of the total experiments for highly accurate predictions. CONCLUSIONS: We show that active learning accuracy can be predicted using simulated data and results in substantial savings in the number of experiments required to make accurate drug-target predictions. BioMed Central 2015-07-09 /pmc/articles/PMC4495685/ /pubmed/26153434 http://dx.doi.org/10.1186/s12859-015-0650-9 Text en © Temerinac-Ott et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Temerinac-Ott, Maja
Naik, Armaghan W
Murphy, Robert F
Deciding when to stop: efficient experimentation to learn to predict drug-target interactions
title Deciding when to stop: efficient experimentation to learn to predict drug-target interactions
title_full Deciding when to stop: efficient experimentation to learn to predict drug-target interactions
title_fullStr Deciding when to stop: efficient experimentation to learn to predict drug-target interactions
title_full_unstemmed Deciding when to stop: efficient experimentation to learn to predict drug-target interactions
title_short Deciding when to stop: efficient experimentation to learn to predict drug-target interactions
title_sort deciding when to stop: efficient experimentation to learn to predict drug-target interactions
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495685/
https://www.ncbi.nlm.nih.gov/pubmed/26153434
http://dx.doi.org/10.1186/s12859-015-0650-9
work_keys_str_mv AT temerinacottmaja decidingwhentostopefficientexperimentationtolearntopredictdrugtargetinteractions
AT naikarmaghanw decidingwhentostopefficientexperimentationtolearntopredictdrugtargetinteractions
AT murphyrobertf decidingwhentostopefficientexperimentationtolearntopredictdrugtargetinteractions